Loading...
•
Jun 30, 2020
Ionis Q2 2020 Earnings Report
Ionis reported financial results for Q2 2020, highlighting commercial and R&D revenue growth and a strong cash position.
Key Takeaways
Ionis Pharmaceuticals reported a net loss of $32 million on a GAAP basis but achieved net income of $8 million on a non-GAAP basis. The company saw growth in commercial and R&D revenues and maintained a strong cash position of over $2.3 billion.
Achieved net income on a non-GAAP basis.
Commercial revenue from SPINRAZA royalties increased to $72 million.
Product sales from TEGSEDI and WAYLIVRA increased to $16 million.
R&D revenue increased to more than $55 million.
Ionis
Ionis
Ionis Revenue by Segment
Revenue by Segment
SPINRAZA royalties Revenue
CapyFin.comTEGSEDI and WAYLIVRA Revenue
CapyFin.com Forward Guidance
Ionis is maintaining its 2020 financial guidance and expects revenue and earnings growth in the second half of this year.
Revenue & Expenses
Visualization of income flow from segment revenue to net income